HOME >> BIOLOGY >> NEWS
Other highlights in the May 19 JNCI

Two Studies Examine Safe Three Agent Combination Therapy for HER2-Positive Advanced Breast Cancer

Combinations of docetaxel, cisplatin or carboplatin, and the monoclonal antibody trastuzumab are feasible for the treatment of patients with HER2-positive advanced breast cancer in which tumor response rates are high, according to two new studies.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in the tumors of 20-30% of breast cancer patients and is associated with an increased risk of relapse and death in patients with early-stage breast cancer. In earlier clinical trials, adding trastuzumab, which blocks the effects of HER2, to standard chemotherapy increased both the response rate of patients and survival, but an unacceptable number of patients experienced cardiac dysfunction, including congestive heart disease.

In the first of two studies designed to find safer chemotherapy combinations that include trastuzumab, Mark D. Pegram, M.D., of the University of California, Los Angeles, and colleagues characterized the interactions between trastuzumab and nine chemotherapy drugs commonly used in treating breast cancer in four cell lines that overexpress HER2. They found synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine, which indicated that these were reasonable combinations to test in human clinical trials.

In the second study, a second group of researchers also led by Pegram, conducted two phase II clinical trials to evaluate the combination of docetaxel and trastuzumab with either of two platinum salts, cisplatin or carboplatin. In each trial, the combinations were tested on 62 women with advanced breast cancer that overexpressed HER2. Both combinations had a similar toxicity to docetaxel plus platinum salts alone, and there was a low incidence of cardiac dysfunction. In addition, overall response rates were higher. The combinations are now being tested
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
18-May-2004


Page: 1 2 3 4

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2020)... BOSTON (PRWEB) , ... June 16, 2020 , ... The ... Ph.D., is betting that if the stem cell medicine and pharmaceutical industries have easier ... their practice. So, starting July 5 of this year, Independence Day weekend in ...
(Date:6/11/2020)... ... 08, 2020 , ... Cryo-Cell International’s announcement comes on the ... in the medical field. The face masks will be distributed nationwide to obstetrical ... day to provide healthcare to pregnant women. The delivery of masks is scheduled ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, ... for a global perspective to make an impact in a post pandemic world,” said ... an independent, director of the company. , “The Greffex board is excited to have ...
Breaking Biology News(10 mins):
(Date:6/11/2020)... ... ... Reducing carbon emissions has been and will continue to be a major topic of ... reduce CO2 is something we can’t avoid. , To protect the environment, oil ... are created from recycled cooking oil or crops. Unfortunately, these sources are not sustainable. ...
(Date:5/28/2020)... Switzerland (PRWEB) , ... May 28, 2020 , ... ... biopharmaceutical R&D, today announced the release of Genedata Screener ® 17.0, the ... of screening data from all in-vitro screening assay technologies. Genedata will host a ...
(Date:5/21/2020)... BALTIMORE (PRWEB) , ... May 19, 2020 , ... Eaton ... with the addition of Popper and Company, a biotechnology and medical technology-focused strategy and ... continues to grow in the United States, linking US and Asia Pacific healthcare innovators ...
(Date:5/15/2020)... LEXINGTON, Mass. (PRWEB) , ... May 15, 2020 , ... ... announced the appointment of Richard Ganz as Executive Chairman. Mr. Ganz will continue ... nine years, as well as work closely with CEO Brian Miller and Sentien’s management ...
Breaking Biology Technology:
Cached News: